A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types
Frontiers in Bioinformatics · 18.08.2026 · 6
DOI: 10.3389/fbinf.2026.1882238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioinformatics, online erschienen am 18.08.2026. Verfasst von Itika Arora und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alfaisal University.
Abstract (Originalsprache)
Drug-tolerant persister (DTP) cells survive therapeutic stress through reversible, non-genetic adaptations, driving treatment failure across cancers. Whether a recurrently perturbed program defines the DTP state across cancer types remains poorly characterized. We performed integrated transcriptomic analysis across five GEO RNA-seq datasets representing breast, lung, pancreatic, colorectal, and melanoma DTP models. A stringent 12-gene signature, PanDTP-12, was established from genes meeting differential expression criteria (FDR <0.001, |log 2 FC| >= 0.8) across four discovery datasets. Module scores showed complete separation between persister and control samples (within-dataset and pooled AUC = 1.0; n = 16), though trivially small per-dataset sample sizes (n = 2–3 per group) preclude interpreting AUC = 1.0 as a stable performance estimate. Sensitivity analysis confirmed that all 12 genes remained recurrent when the fasting-quiescence dataset GSE214537 was excluded. In an independent PC9 NSCLC dataset (GSE255958), PanDTP-12 showed high directional concordance (9/12 genes) and quantitative module-score separation between parental PC9D and day-9 persister PC9O9 samples (AUC = 1.0, Cohen’s d = 14.76), though these metrics are based on only 6 samples and should be interpreted with caution. INK128-induced DTP models in MCF-7 and HCT116 cells demonstrated cell-cycle arrest, morphological changes, and RT-qPCR confirmation of PanDTP-12 upregulation (12/12 significant in HCT116; 6/12 in MCF-7). Drug-repurposing analysis identified focused drug-gene interactions among PanDTP-12 members. These findings identify PanDTP-12 as a recurrently perturbed twelve-gene program marking the DTP state across cancer types. The signature offers focused pharmacological hypotheses through druggable members (CLK1, XBP1, and KLF5) and establishes a framework for translational assessment of DTP-directed therapeutics, though larger validation cohorts and functional studies will be needed to confirm clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
- Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Förderung
- Alfaisal University
Zitieren
APA
Arora, I., Adam, A. M., Aljaylani, A. O., Alzuhayri, J. Z., Ali, E. M. M., Alzahrani, F. A., Khan, M. I., & Yaqinuddin, A. (2026). A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types. Frontiers in Bioinformatics, 6. https://doi.org/10.3389/fbinf.2026.1882238
Vancouver
Arora I, Adam AM, Aljaylani AO, Alzuhayri JZ, Ali EMM, Alzahrani FA, et al. A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types. Frontiers in Bioinformatics. 2026;6. doi:10.3389/fbinf.2026.1882238
BibTeX
@article{Arora2026,
author = {Arora, Itika and Adam, Ahmed Mohammed and Aljaylani, Abdullah O and Alzuhayri, Jumana Z and Ali, Ehab M M and Alzahrani, Faisal A and Khan, Mohammad Imran and Yaqinuddin, Ahmed},
title = {A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types},
journal = {Frontiers in Bioinformatics},
year = {2026},
volume = {6},
doi = {10.3389/fbinf.2026.1882238}
}
EUVIMED